The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Systemic and mucosal antibody responses specific to SARS-CoV-2 during mild versus severe COVID-19
Open accessPublished version of a preprint
Abstract
Abstract Background Infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes an acute illness termed coronavirus disease 2019 (COVID-19). Humoral immune responses likely play an important role in containing SARS-CoV-2, however, the determinants of SARS-CoV-2-specific antibody responses are unclear. Methods Using immunoassays specific for the SARS-CoV-2 spike protein, we determined SARS-CoV-2-specific immunoglobulin A (IgA) and immunoglobulin G (IgG) in sera and mucosal fluids of two cohorts, including patients with quantitative reverse-transcriptase polymerase chain reaction (RT-qPCR)-confirmed SARS-CoV-2 infection (n = 56; median age 61 years) with mild versus severe COVID-19, and SARS-CoV-2-exposed healthcare workers (n = 109; median age 36 years) with or without symptoms and tested negative or positive by RT-qPCR. Findings On average, SARS-CoV-2-specific serum IgA titers in mild COVID-19 cases became positive eight days after symptom onset and were often transient, whereas serum IgG levels remained negative or reached positive values 9–10 days after symptom onset. Conversely, patients with severe COVID-19 showed a highly significant increase of SARS-CoV-2-specific serum IgA and IgG titers as a function of duration since symptom onset, independent of patient age and comorbidities. Very high levels of SARS-CoV-2-specific serum IgA correlated with severe acute respiratory distress syndrome (ARDS). Interestingly, some of the SARS-CoV-2-exposed healthcare workers with negative SARS-CoV-2-specific IgA and IgG serum titers had detectable SARS-CoV-2-specific IgA antibodies in their nasal fluids and tears. Moreover, SARS-CoV-2-specific IgA levels in nasal fluids of these healthcare workers were inversely correlated with patient age. Interpretation These data show that systemic IgA and IgG production against SARS-CoV-2 develops mainly in severe COVID-19, with very high IgA levels seen in patients with severe ARDS, whereas mild disease may be associated with transient serum titers of SARS-CoV-2-specific antibodies but stimulate mucosal SARS-CoV-2-specific IgA secretion. The findings suggest four grades of antibody responses dependent on COVID-19 severity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A novel coronavirus from patients with pneumonia in China, 2019
Zhu, N., Zhang, D., Wang, W., Li, X., Yang, B., Song, J., Zhao, X., Huang, B., Shi, W., Lu, R., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001017 · Cited by 28,244
Zhou, F., Yu, T., Du, R., Fan, G., Liu, Y., Liu, Z., Xiang, J., Wang, Y., Song, B., Gu, X., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30566-3 · Cited by 27,263
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
Wu, Z., & McGoogan, J. M. (2020) · JAMA · doi:10.1001/jama.2020.2648 · Cited by 17,016
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Yang, X., Yu, Y., Xu, J., Shu, H., Xia, J., Liu, H., Wu, Y., Zhang, L., Yu, Z., Fang, M., et al. (2020) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(20)30079-5 · Cited by 10,066
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048
Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Acute Respiratory Distress Syndrome: The Berlin Definition
(2012) · JAMA · doi:10.1001/jama.2012.5669 · Cited by 8,731
Coronaviridae Study Group of the International Committee on Taxonomy of Viruses, Gorbalenya, A. E., Baker, S. C., Baric, R. S., de Groot, R. J., Drosten, C., Gulyaeva, A. A., Haagmans, B. L., Lauber, C., Leontovich, A. M., et al. (2020) · Nature Microbiology · doi:10.1038/s41564-020-0695-z · Cited by 8,403
The trinity of COVID-19: immunity, inflammation and intervention
Tay, M. Z., Poh, C. M., Rénia, L., MacAry, P. A., & Ng, L. F. P. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0311-8 · Cited by 4,360
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222
Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yang, Y.-B., Yan, Y.-Q., Akdis, C. A., & Gao, Y.-D. (2020) · Allergy · doi:10.1111/all.14238 · Cited by 4,004
Li, R., Pei, S., Chen, B., Song, Y., Zhang, T., Yang, W., & Shaman, J. (2020) · Science · doi:10.1126/science.abb3221 · Cited by 3,633
Ou, X., Liu, Y., Lei, X., Li, P., Mi, D., Ren, L., Guo, L., Guo, R., Chen, T., Hu, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15562-9 · Cited by 3,097
To, K. K.-W., Tsang, O. T.-Y., Leung, W.-S., Tam, A. R., Wu, T.-C., Lung, D. C., Yip, C. C.-Y., Cai, J.-P., Chan, J. M.-C., Chik, T. S.-H., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30196-1 · Cited by 3,066
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
The role of senescent cells in ageing
van Deursen, J. M. (2014) · Nature · doi:10.1038/nature13193 · Cited by 2,623
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Shen, C., Wang, Z., Zhao, F., Yang, Y., Li, J., Yuan, J., Wang, F., Li, D., Yang, M., Xing, L., et al. (2020) · JAMA · doi:10.1001/jama.2020.4783 · Cited by 2,277
Presymptomatic SARS-CoV-2 Infections and Transmission in a Skilled Nursing Facility
Arons, M. M., Hatfield, K. M., Reddy, S. C., Kimball, A., James, A., Jacobs, J. R., Taylor, J., Spicer, K., Bardossy, A. C., Oakley, L. P., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2008457 · Cited by 2,052
Viral dynamics in mild and severe cases of COVID-19
Liu, Y., Yan, L.-M., Wan, L., Xiang, T.-X., Le, A., Liu, J.-M., Peiris, M., Poon, L. L. M., & Zhang, W. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30232-2 · Cited by 1,727
Nonparametric Statistical Methods
Ramsey, P. H. (2000) · Technometrics · doi:10.1080/00401706.2000.10486020 · Cited by 1,673
Immune response to SARS‐CoV‐2 and mechanisms of immunopathological changes in COVID‐19
Azkur, A. K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M., O’Mahony, L., Gao, Y., Nadeau, K., & Akdis, C. A. (2020) · Allergy · doi:10.1111/all.14364 · Cited by 1,119
Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent Individuals
Ni, L., Ye, F., Cheng, M.-L., Feng, Y., Deng, Y.-Q., Zhao, H., Wei, P., Ge, J., Gou, M., Li, X., et al. (2020) · Immunity · doi:10.1016/j.immuni.2020.04.023 · Cited by 1,063
Thissen, D., Steinberg, L., & Kuang, D. (2002) · Journal of Educational and Behavioral Statistics · doi:10.3102/10769986027001077 · Cited by 974
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans
Ng, K. W., Faulkner, N., Cornish, G. H., Rosa, A., Harvey, R., Hussain, S., Ulferts, R., Earl, C., Wrobel, A. G., Benton, D. J., et al. (2020) · Science · doi:10.1126/science.abe1107 · Cited by 886
Liu, L., Wei, Q., Lin, Q., Fang, J., Wang, H., Kwok, H., Tang, H., Nishiura, K., Peng, J., Tan, Z., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.123158 · Cited by 830
Brodin, P., & Davis, M. M. (2017) · Nature reviews. Immunology · doi:10.1038/nri.2016.125 · Cited by 730
The time course of the immune response to experimental coronavirus infection of man
Callow, K. A., Parry, H. F., Sergeant, M., & Tyrrell, D. A. J. (1990) · Epidemiology and Infection · doi:10.1017/s0950268800048019 · Cited by 598
Potential Presymptomatic Transmission of SARS-CoV-2, Zhejiang Province, China, 2020
Tong, Z.-D., Tang, A., Li, K.-F., Li, P., Wang, H.-L., Yi, J.-P., Zhang, Y.-L., & Yan, J.-B. (2020) · Emerging Infectious Diseases · doi:10.3201/eid2605.200198 · Cited by 463
Successful and Maladaptive T Cell Aging
Goronzy, J. J., & Weyand, C. M. (2017) · Immunity · doi:10.1016/j.immuni.2017.03.010 · Cited by 362
Mechanisms that determine plasma cell lifespan and the duration of humoral immunity
Amanna, I. J., & Slifka, M. K. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00912.x · Cited by 343
Distinct features of SARS-CoV-2-specific IgA response in COVID-19 patients
Yu, H.-Q., Sun, B.-Q., Fang, Z.-F., Zhao, J.-C., Liu, X.-Y., Li, Y.-M., Sun, X.-Z., Liang, H.-F., Zhong, B., Huang, Z.-F., et al. (2020) · European Respiratory Journal · doi:10.1183/13993003.01526-2020 · Cited by 321
Hu, Y., Li, W., Gao, T., Cui, Y., Jin, Y., Li, P., Ma, Q., Liu, X., & Cao, C. (2017) · Journal of Virology · doi:10.1128/jvi.02143-16 · Cited by 294
Systematic Review of Safety and Efficacy of Rituximab in Treating Immune-Mediated Disorders
Kaegi, C., Wuest, B., Schreiner, J., Steiner, U. C., Vultaggio, A., Matucci, A., Crowley, C., & Boyman, O. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01990 · Cited by 260
Self-citationValidation of a commercially available SARS-CoV-2 serological immunoassay
Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm‐Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., et al. (2020) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2020.06.024 · Cited by 168
A distinct innate immune signature marks progression from mild to severe COVID-19
Chevrier, S., Zurbuchen, Y., Cervia, C., Adamo, S., Raeber, M. E., de Souza, N., Sivapatham, S., Jacobs, A., Bächli, E., Rudiger, A., et al. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100166 · Cited by 157
Self-citationViral Evasion Strategies in Type I IFN Signaling – A Summary of Recent Developments
Schulz, K. S., & Mossman, K. L. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00498 · Cited by 146
V’kovski, P., Gultom, M. L., Kelly, J. N., Steiner, S., Russeil, J., Mangeat, B., Cora, E., Pezoldt, J., Holwerda, M., Kratzel, A., et al. (2021) · PLoS Biology · doi:10.1371/journal.pbio.3001158 · Cited by 140
Serology for SARS-CoV-2: Apprehensions, opportunities, and the path forward
Bryant, J. E., Azman, A. S., Ferrari, M. J., Arnold, B. F., Boni, M. F., Boum, Y., Hayford, K. T., Luquero, F. J., Mina, M. J., Rodríguez-Barraquer, I., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abc6347 · Cited by 137
Chan, C.-M., Tse, H., Wong, S. S. Y., Woo, P. C. Y., Lau, S. K. P., Chen, L., Zheng, B. J., Huang, J., & Yuen, K. (2009) · Journal of Clinical Virology · doi:10.1016/j.jcv.2009.02.011 · Cited by 92
V’kovski, P., Gultom, M. L., Kelly, J. N., Steiner, S., Russeil, J., Mangeat, B., Cora, E., Pezoldt, J., Holwerda, M., Kratzel, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.04.27.062315 · Cited by 53
Emmenegger, M., Cecco, E. D., Lamparter, D., Jacquat, R. P. B., Riou, J., Menges, D., Ballouz, T., Ebner, D. V., Schneider, M. M., Morales, I. C., et al. (2023) · iScience · doi:10.1101/2020.05.31.20118554 · Cited by 34
Self-citationValidation of a commercially available SARS-CoV-2 serological ImmunoassayPreprint
Meyer, B., Torriani, G., Yerly, S., Mazza, L., Calame, A., Arm‐Vernez, I., Zimmer, G., Agoritsas, T., Stirnemann, J., Spechbach, H., et al. (2020) · medRxiv · doi:10.1101/2020.05.02.20080879 · Cited by 33
Lymphopenia-induced T cell proliferation is a hallmark of severe COVID-19Preprint
Adamo, S., Chevrier, S., Cervia, C., Zurbuchen, Y., Raeber, M. E., Yang, L., Sivapatham, S., Jacobs, A., Bächli, E., Rudiger, A., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.08.04.236521 · Cited by 23
Self-citationA distinct innate immune signature marks progression from mild to severe COVID-19Preprint
Chevrier, S. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.17632/vyy8ttw7n9 · Cited by 13
Cited by
Persistence of serum and saliva antibody responses to SARS-CoV-2 spike antigens in COVID-19 patients
Isho, B., Abe, K. T., Zuo, M., Jamal, A. J., Rathod, B., Wang, J. H., Li, Z., Chao, G., Rojas, O. L., Bang, Y. M., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe5511 · Cited by 822
Infection fatality rate of COVID-19 inferred from seroprevalence data
Ioannidis, J. P. A. (2021) · Bulletin of the World Health Organization · doi:10.2471/blt.20.265892 · Cited by 684
The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review
Oran, D. P., & Topol, E. J. (2021) · Annals of Internal Medicine · doi:10.7326/m20-6976 · Cited by 533
Zimmermann, P., & Curtis, N. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2020-320338 · Cited by 502
Röltgen, K., Powell, A. E., Wirz, O. F., Stevens, B. A., Hogan, C. A., Najeeb, J., Hunter, M., Wang, H., Sahoo, M. K., Huang, C., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.abe0240 · Cited by 452
Metadata
- Authors
- Cervia, C., Nilsson, J., Zurbuchen, Y., Valaperti, A., Schreiner, J., Wolfensberger, A., Raeber, M. E., Adamo, S., Weigang, S., Emmenegger, M., Hasler, S., Bosshard, P. P., De Cecco, E., Bächli, E., Rudiger, A., Stüssi-Helbling, M., Huber, L. C., Zinkernagel, A. S., Schaer, D. J., Aguzzi, A., Kochs, G., Held, U., Probst-Müller, E., Rampini, S. K., & Boyman, O.
- Venue
- Journal of Allergy and Clinical Immunology
- Publisher
- Elsevier BV
- Published
- 2021-02
- Volume
- 147
- Issue
- 2
- Pages
- 545-557.e9
- ISSN
- 0091-6749 (ISSN-L)
- OpenAlex
- W3098118792
- Cited by
- 408
- References
- 48
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
- Funders
- Universität Zürich
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030-172978, 4078P0-198431)
- Universitätsspital Zürich
- Deutsches Zentrum für Luft- und Raumfahrt
- Bundesministerium für Bildung und Forschung (01KI2077)
- Schweizerische Akademie der Medizinischen Wissenschaften (YTCR 32/18, 323530-177975, 323530-191230, 323530-191220)
- Gottfried und Julia Bangerter-Rhyner-Stiftung
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.